Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

Next PostNew Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®